Eligible Population: Understand where RSV candidates have gained approval and which populations are eligible to receive these newly approved vaccines and prophylactics. This expanded functionality allows you to:

→ Identify which markets RSV candidates have gained approval in

→ See how the eligible populations in each market differs

→ Compare the timelines of approvals in different markets

→ Understand nuances of approvals and roll-out with extra information provided e.g. shared decision making

Pricing Data: Access all publicly available pricing data across vaccines and prophylactics including public and private pricing across markets, income bands and regions. This allows you to compare pricing data across market, region, income band, country and candidate

Revenue Data: Q3 revenue data has recently been released for the first time from Sanofi for Nirsevimab, and from GSK and Pfizer for their RSV vaccines. These new reported revenue figures are now available on the platform, alongside previous reported revenues for Palivizumab. These will continue to be tracked and updated as new revenue data is released.